Literature DB >> 19729451

ADAMTS13 bound to endothelial cells exhibits enhanced cleavage of von Willebrand factor.

Anthony N Vomund1, Elaine M Majerus.   

Abstract

ADAMTS13 is a plasma metalloprotease that cleaves ultralarge von Willebrand factor multimers to generate less thrombogenic fragments. Although this cleavage can occur at the surface of endothelial cells, it is currently unknown whether this process involves binding of the ADAMTS13 to the endothelial cell plasma membrane. Using different assay systems, we present evidence that ADAMTS13 binds to endothelial cells in a specific, reversible, and time-dependent manner with a K(d) of 58 nm. This binding requires the COOH-terminal thrombospondin type 1 repeats of the protease. Binding is inhibited in the presence of heparin and by trypsin treatment of the cells. ADAMTS13 that was prebound to endothelial cells exhibited increased proteolysis of VWF as compared with ADAMTS13 present only in solution. These data support the notion that cleavage of VWF occurs mainly at the endothelial cell surface.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19729451      PMCID: PMC2781492          DOI: 10.1074/jbc.M109.000927

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

1.  Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.

Authors:  Xinglong Zheng; Kenji Nishio; Elaine M Majerus; J Evan Sadler
Journal:  J Biol Chem       Date:  2003-06-05       Impact factor: 5.157

2.  Temperature dependence of endocytosis mediated by the asialoglycoprotein receptor in isolated rat hepatocytes. Evidence for two potentially rate-limiting steps.

Authors:  P H Weigel; J A Oka
Journal:  J Biol Chem       Date:  1981-03-25       Impact factor: 5.157

3.  ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.

Authors:  Kenji Soejima; Masanori Matsumoto; Koichi Kokame; Hideo Yagi; Hiromichi Ishizashi; Hiroaki Maeda; Chikateru Nozaki; Toshiyuki Miyata; Yoshihiro Fujimura; Tomohiro Nakagaki
Journal:  Blood       Date:  2003-07-17       Impact factor: 22.113

4.  Properties of the factor Xa binding site on human platelets.

Authors:  J P Miletich; C M Jackson; P W Majerus
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

5.  P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface.

Authors:  Arnoldo Padilla; Joel L Moake; Aubrey Bernardo; Chalmette Ball; Yongtao Wang; Maneesh Arya; Leticia Nolasco; Nancy Turner; Michael C Berndt; Bahman Anvari; José A López; Jing-Fei Dong
Journal:  Blood       Date:  2003-11-20       Impact factor: 22.113

6.  Synthesis of von Willebrand factor by cultured human endothelial cells.

Authors:  E A Jaffe; L W Hoyer; R L Nachman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-05       Impact factor: 11.205

7.  Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress.

Authors:  Jing Huang; Robyn Roth; John E Heuser; J Evan Sadler
Journal:  Blood       Date:  2008-10-16       Impact factor: 22.113

8.  ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.

Authors:  Jing-fei Dong; Joel L Moake; Leticia Nolasco; Aubrey Bernardo; Wendy Arceneaux; Corie N Shrimpton; Alicia J Schade; Larry V McIntire; Kazuo Fujikawa; José A López
Journal:  Blood       Date:  2002-07-25       Impact factor: 22.113

9.  Synthesis of factor VIII antigen by cultured guinea pig megakaryocytes.

Authors:  R Nachman; R Levine; E A Jaffe
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

10.  Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells.

Authors:  D D Wagner; J B Olmsted; V J Marder
Journal:  J Cell Biol       Date:  1982-10       Impact factor: 10.539

View more
  7 in total

1.  Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Haifeng M Wu; Dezhi Shang; Erica Falls; Christopher G Skipwith; Spero R Cataland; Charles L Bennett; Hau C Kwaan
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

Review 2.  Structure-function and regulation of ADAMTS-13 protease.

Authors:  X L Zheng
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

3.  ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 1. Structural and functional characterization in vitro.

Authors:  Eric M Ostertag; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; X Long Zheng; Douglas B Cines; Don L Siegel
Journal:  Transfusion       Date:  2016-04-04       Impact factor: 3.157

4.  Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study.

Authors:  Moritz Lambers; Neil A Goldenberg; Gili Kenet; Fenella J Kirkham; Daniela Manner; Timothy Bernard; Rolf M Mesters; Ralf Junker; Monika Stoll; Ulrike Nowak-Göttl
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

5.  Phenotypic expression of ADAMTS13 in glomerular endothelial cells.

Authors:  Ramesh Tati; Ann-Charlotte Kristoffersson; Anne-Lie Ståhl; Matthias Mörgelin; David Motto; Simon Satchell; Peter Mathieson; Minola Manea-Hedström; Diana Karpman
Journal:  PLoS One       Date:  2011-06-24       Impact factor: 3.240

Review 6.  Endothelium--role in regulation of coagulation and inflammation.

Authors:  Victor W M van Hinsbergh
Journal:  Semin Immunopathol       Date:  2011-08-04       Impact factor: 9.623

7.  mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice.

Authors:  Susan Liu-Chen; Brendan Connolly; Lei Cheng; Romesh R Subramanian; Zhaozhong Han
Journal:  Sci Rep       Date:  2018-05-18       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.